BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

A 48-Year-Old Man With Recurrent Nasopharyngeal Carcinoma and a 53-Year-Old Woman With Metastatic Nasopharyngeal Carcinoma

Video Series

Case Based Peer Perspectives

Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology 

Video content above is prompted by the following:

The patient from Case 1 received induction chemotherapy followed by concurrent chemoradiation as initial treatment following diagnosis.

What are your thoughts on this treatment regimen given the disease presentation/diagnosis?

How does elevated Epstein-Barr virus DNA impact your radiation treatment decision?

What parameters would you monitor to assess response during and after radiation therapy?

Videos

An expert discusses the clinical challenges and management strategies for a 48-year-old man with recurrent nasopharyngeal carcinoma and a 53-year-old woman with metastatic nasopharyngeal carcinoma.

An expert discusses the use of toripalimab in the treatment of recurrent and metastatic nasopharyngeal carcinoma (NPC) through clinical case introductions.

Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC 

An expert discusses key considerations for nasopharyngeal carcinoma (NPC) therapy from the perspective of radiation oncology.

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for re-irradiation, while also reflecting on the treatment strategy in Case 2 and the criteria for determining whether the patient would benefit from additional radiation therapy.

Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, and other relevant methods.

Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging

An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how findings from Liu et al (Lancet, 2024) inform the evolving treatment landscape.

Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment 

Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology

EP: 1.Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC

EP: 2.Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology

EP: 3.Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

EP: 4.Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging

EP: 5.Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment

Newsletter